Efecto diferencial sobre el IGF-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicas

Tibolone has estrogenic, androgenic and progestational effects and is used in post menopausal women. It apparently has weaker effects on endometrial proliferation and mammary stimulation than conventional hormone replacement therapy. Aim: To compare the metabolic effects of tibolone (5 mg/day) and c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Porcile,Arnaldo, Gallardo,Enrique, Duarte,Patricia, Aedo,Sócrates
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2003
Materias:	Estrogens insulin-like growth factor 1 medroxyprogesterone tibolone
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872003001000008
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872003001000008
record_format	dspace
spelling	oai:scielo:S0034-988720030010000082004-12-07Efecto diferencial sobre el IGF-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicasPorcile,ArnaldoGallardo,EnriqueDuarte,PatriciaAedo,Sócrates Estrogens insulin-like growth factor 1 medroxyprogesterone tibolone Tibolone has estrogenic, androgenic and progestational effects and is used in post menopausal women. It apparently has weaker effects on endometrial proliferation and mammary stimulation than conventional hormone replacement therapy. Aim: To compare the metabolic effects of tibolone (5 mg/day) and continuous combined conjugated estrogens/medroxyprogesterone acetate in postmenopausal women. Patients and Methods: postmenopausal women, aged 45 to 60 years old, receiving estradiol valerate and medroxyprogesterone were included in the study. After a two months wash out period, in a double blind fashion, they were randomly assigned to oral tibolone 5 mg/day or equine conjugated estrogens 0.625 mg + medroxiprogesterone acetate 2.5 mg/day (ECE/MPA). At baseline, 30 and 45 days of treatment, fasting serum osteocalcin, somatomedin C (IGF-1, insulin-like growth factor 1), growth hormone (GH), and follicle stimulating hormone and first morning urine calcium and creatinine were measured. Results: Thirty women were studied. There was more than 50% fall in urine calcium with either tibolone or ECE/MPA, while fasting GH or osteocalcin did not show significant changes. Serum IGF-1 increased significantly with tibolone at basal, 30 (+109%) and 45 days of treatment and did not change in the ECE/MPA group. Conclusions: Tibolone (5 mg/day) and ECE/MPA induced a similar reduction in urinary calcium. Tibolone increased serum IGF-1 levels. This may be due to undetected increment of overall GH secretion or to a specific action on IGF-1 generation from the liver and appears to be a novel differential effect of tibolone (Rev Méd Chile 2003; 131: 1151-56).info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.131 n.10 20032003-10-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872003001000008es10.4067/S0034-98872003001000008
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Estrogens insulin-like growth factor 1 medroxyprogesterone tibolone
spellingShingle	Estrogens insulin-like growth factor 1 medroxyprogesterone tibolone Porcile,Arnaldo Gallardo,Enrique Duarte,Patricia Aedo,Sócrates Efecto diferencial sobre el IGF-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicas
description	Tibolone has estrogenic, androgenic and progestational effects and is used in post menopausal women. It apparently has weaker effects on endometrial proliferation and mammary stimulation than conventional hormone replacement therapy. Aim: To compare the metabolic effects of tibolone (5 mg/day) and continuous combined conjugated estrogens/medroxyprogesterone acetate in postmenopausal women. Patients and Methods: postmenopausal women, aged 45 to 60 years old, receiving estradiol valerate and medroxyprogesterone were included in the study. After a two months wash out period, in a double blind fashion, they were randomly assigned to oral tibolone 5 mg/day or equine conjugated estrogens 0.625 mg + medroxiprogesterone acetate 2.5 mg/day (ECE/MPA). At baseline, 30 and 45 days of treatment, fasting serum osteocalcin, somatomedin C (IGF-1, insulin-like growth factor 1), growth hormone (GH), and follicle stimulating hormone and first morning urine calcium and creatinine were measured. Results: Thirty women were studied. There was more than 50% fall in urine calcium with either tibolone or ECE/MPA, while fasting GH or osteocalcin did not show significant changes. Serum IGF-1 increased significantly with tibolone at basal, 30 (+109%) and 45 days of treatment and did not change in the ECE/MPA group. Conclusions: Tibolone (5 mg/day) and ECE/MPA induced a similar reduction in urinary calcium. Tibolone increased serum IGF-1 levels. This may be due to undetected increment of overall GH secretion or to a specific action on IGF-1 generation from the liver and appears to be a novel differential effect of tibolone (Rev Méd Chile 2003; 131: 1151-56).
author	Porcile,Arnaldo Gallardo,Enrique Duarte,Patricia Aedo,Sócrates
author_facet	Porcile,Arnaldo Gallardo,Enrique Duarte,Patricia Aedo,Sócrates
author_sort	Porcile,Arnaldo
title	Efecto diferencial sobre el IGF-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicas
title_short	Efecto diferencial sobre el IGF-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicas
title_full	Efecto diferencial sobre el IGF-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicas
title_fullStr	Efecto diferencial sobre el IGF-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicas
title_full_unstemmed	Efecto diferencial sobre el IGF-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicas
title_sort	efecto diferencial sobre el igf-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicas
publisher	Sociedad Médica de Santiago
publishDate	2003
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872003001000008
work_keys_str_mv	AT porcilearnaldo efectodiferencialsobreeligf1sericodetibolona5mgdiavscombinadocontinuodeestrogenoprogestinaenmujerespostmenopausicas AT gallardoenrique efectodiferencialsobreeligf1sericodetibolona5mgdiavscombinadocontinuodeestrogenoprogestinaenmujerespostmenopausicas AT duartepatricia efectodiferencialsobreeligf1sericodetibolona5mgdiavscombinadocontinuodeestrogenoprogestinaenmujerespostmenopausicas AT aedosocrates efectodiferencialsobreeligf1sericodetibolona5mgdiavscombinadocontinuodeestrogenoprogestinaenmujerespostmenopausicas
_version_	1718436116451819520

Efecto diferencial sobre el IGF-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicas

Ejemplares similares